AXGN
Price
$17.41
Change
+$0.24 (+1.40%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
348.67M
49 days until earnings call
CERS
Price
$1.48
Change
+$0.01 (+0.68%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
342.62M
50 days until earnings call
Ad is loading...

AXGN vs CERS

Header iconAXGN vs CERS Comparison
Open Charts AXGN vs CERSBanner chart's image
Axogen
Price$17.41
Change+$0.24 (+1.40%)
Volume$7.33K
Capitalization348.67M
Cerus
Price$1.48
Change+$0.01 (+0.68%)
Volume$15.16K
Capitalization342.62M
AXGN vs CERS Comparison Chart
Loading...
AXGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXGN vs. CERS commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXGN is a StrongBuy and CERS is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (AXGN: $17.18 vs. CERS: $1.47)
Brand notoriety: AXGN and CERS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: AXGN: 136% vs. CERS: 119%
Market capitalization -- AXGN: $348.67M vs. CERS: $342.62M
AXGN [@Medical Specialties] is valued at $348.67M. CERS’s [@Medical Specialties] market capitalization is $342.62M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXGN’s FA Score shows that 0 FA rating(s) are green whileCERS’s FA Score has 0 green FA rating(s).

  • AXGN’s FA Score: 0 green, 5 red.
  • CERS’s FA Score: 0 green, 5 red.
According to our system of comparison, both AXGN and CERS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXGN’s TA Score shows that 3 TA indicator(s) are bullish while CERS’s TA Score has 2 bullish TA indicator(s).

  • AXGN’s TA Score: 3 bullish, 6 bearish.
  • CERS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, AXGN is a better buy in the short-term than CERS.

Price Growth

AXGN (@Medical Specialties) experienced а -10.94% price change this week, while CERS (@Medical Specialties) price change was -3.92% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.36%. For the same industry, the average monthly price growth was -7.35%, and the average quarterly price growth was -3.83%.

Reported Earning Dates

AXGN is expected to report earnings on Apr 30, 2025.

CERS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Medical Specialties (-1.36% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXGN($349M) and CERS($343M) have the same market capitalization . AXGN YTD gains are higher at: 4.248 vs. CERS (-4.545). AXGN has higher annual earnings (EBITDA): -13.33M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. AXGN (31M). AXGN has less debt than CERS: AXGN (69.3M) vs CERS (96M). AXGN (159M) and CERS (156M) have equivalent revenues.
AXGNCERSAXGN / CERS
Capitalization349M343M102%
EBITDA-13.33M-26.34M51%
Gain YTD4.248-4.545-93%
P/E RatioN/AN/A-
Revenue159M156M102%
Total Cash31M65.9M47%
Total Debt69.3M96M72%
FUNDAMENTALS RATINGS
AXGN vs CERS: Fundamental Ratings
AXGN
CERS
OUTLOOK RATING
1..100
6459
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
8993
PRICE GROWTH RATING
1..100
9496
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (46) in the Medical Specialties industry is in the same range as AXGN (48). This means that CERS’s stock grew similarly to AXGN’s over the last 12 months.

AXGN's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as CERS (100). This means that AXGN’s stock grew similarly to CERS’s over the last 12 months.

AXGN's SMR Rating (89) in the Medical Specialties industry is in the same range as CERS (93). This means that AXGN’s stock grew similarly to CERS’s over the last 12 months.

AXGN's Price Growth Rating (94) in the Medical Specialties industry is in the same range as CERS (96). This means that AXGN’s stock grew similarly to CERS’s over the last 12 months.

AXGN's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as CERS (100). This means that AXGN’s stock grew similarly to CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXGNCERS
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 5 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 15 days ago
80%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
AXGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PHSZX43.89N/A
N/A
PGIM Jennison Health Sciences Z
MITTX35.81N/A
N/A
MFS Massachusetts Investors Tr A
BTBFX61.88N/A
N/A
Boston Trust Asset Management
BGGSX25.01N/A
N/A
Baillie Gifford US Equity Growth I
RYVPX6.81-0.27
-3.81%
Royce Smaller-Companies Growth Svc

AXGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXGN has been loosely correlated with TCMD. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AXGN jumps, then TCMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXGN
1D Price
Change %
AXGN100%
-3.10%
TCMD - AXGN
43%
Loosely correlated
-2.96%
ICUI - AXGN
39%
Loosely correlated
-8.40%
TMDX - AXGN
38%
Loosely correlated
-2.12%
CERS - AXGN
35%
Loosely correlated
-2.65%
VMD - AXGN
35%
Loosely correlated
-1.33%
More

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-2.65%
LAB - CERS
44%
Loosely correlated
-6.47%
MASS - CERS
41%
Loosely correlated
+9.24%
OFIX - CERS
40%
Loosely correlated
-2.39%
ICUI - CERS
39%
Loosely correlated
-8.40%
NNOX - CERS
39%
Loosely correlated
-10.02%
More